| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2016-06-04 | aglatimagene besadenovec (AdV-tk) followed by valacyclovir | malignant pleural effusion | 1b | Advantagene (USA - MA) | Cancer - Oncology |
| 2016-06-03 | BAY-1841788/ODM-201 in combination with standard androgen deprivation therapy and docetaxel | metastatic hormone sensitive prostate cancer | 3 | Orion Corporation (Finland) Bayer (Germany) | Cancer - Oncology |
| 2016-06-03 | Actimab-A - Lintuzumab-Ac225 | newly diagnosed acute myeloid leukemia (AML) in elderly patients | 1-2 | Actinium Pharmaceuticals (USA - NJ) | Cancer - Oncology |
| 2016-06-03 | abemaciclib (LY2835219) | metastatic breast cancer | 2 | Eli Lilly (USA - IN) | Cancer - Oncology |
| 2016-06-02 | TG02 and pembrolizumab | locally recurrent RAS mutated rectal cancer | 1 | Targovax (Norway) | Cancer - Oncology |
| 2016-06-02 | ofatumumab | relapsing multiple sclerosis | 3 | Novartis (Switzerland) | Neurodegenerative diseases |
| 2016-06-02 | ofatumumab | relapsing multiple sclerosis | 3 | Novartis (Switzerland) | Neurodegenerative diseases |
| 2016-06-02 | Beleodaq® oral formulation (belinostat) | preclinical | Onxeo (France) | Cancer - Oncology - Rare diseases | |
| 2016-06-02 | Xtandi® (enzalutamide) and paclitaxell | triple-negative breast cancer (TNBC) | 3 | Medivation (USA - CA) Astellas (Japan) | Cancer - Oncology |
| 2016-06-02 | Pseudomonas aeruginosa vaccine IC43/VLA43 | Pseudomonas aeruginosa infection | 2-3 | Intercell now Valneva (France - Austria) Novartis (Switzerland) | Infectious diseases |
| 2016-06-01 | anamorelin | non-small cell lung cancer (NSCLC) | 3 | Helsinn Group (Switzerland) | Cancer - Oncology |
| 2016-06-01 | Catena®/Raxone® (idebenone) | Duchenne Muscular Dystrophy (DMD) | 3 | Santhera Pharmaceuticals (Switzerland) | Genetic diseases - Neuromuscular diseases - Rare diseases |
| 2016-06-00 | cobimetinib and atezolizumab | colorectal cancer | 3 | Roche (Switzerland) | Cancer - Oncology |
| 2016-05-31 | MBX-8025 (2-[4-[[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) lysine dihydrate) | primary biliary cholangitis | 2 | Cymabay Therapeutics (USA - CA) | Rare diseases - Hepatic diseases - Liver diseases |
| 2016-05-31 | AP32788 | non-small cell lung cancer (NSCLC) with specific mutations in EGFR or HER2 | 1 | Ariad Pharmaceuticals (USA - MA) | Cancer - Oncology |
| 2016-05-31 | evinacumab (REGN1500) | homozygous familial hypercholesterolemia | 2 | Regeneron Pharmaceuticals (USA - NY) | Rare diseases - Genetic diseases - Metabolic diseases |
| 2016-05-31 | prurisol | moderate chronic plaque psoriasis | 2a | Innovation Pharmaceuticals (USA - MA) | Autoimmune diseases - Dermatological diseases |
| 2016-05-27 | betrixaban | prevention of venous thromboembolism (VTE) | 3 | Portola Pharmaceuticals | Cardiovascular diseases |
| 2016-05-27 | Gazyva®/Gazyvaro® (obinutuzumab) | non-Hodgkin's lymphoma | 3 | Roche (Switzerland) | Cancer - Oncology |
| 2016-05-26 | OvaSave® (antigen-specific type 1 regulatory T (Ag-Treg) cell based immunotherapy) | preclinical | Txcell (France) |
